Danaher (DHR) – Company Press Releases
-
Cepheid Announces World Health Organization Prequalification of Xpert HIV-1 Qualitative Test
-
Danaher Schedules First Quarter 2024 Earnings Conference Call
-
Cepheid Receives FDA Clearance for Xpert® Xpress GBS
-
Danaher to Present at TD Cowen Health Care Conference
-
DANAHER ALERT: Bragar Eagel & Squire, P.C. is Investigating Danaher Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
-
Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets
-
Danaher Announces Quarterly Dividend
-
Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development
-
Danaher Reports Fourth Quarter and Full Year 2023 Results
-
DANAHER ALERT: Bragar Eagel & Squire, P.C. is Investigating Danaher Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
-
Cepheid Receives Expanded FDA Clearance with CLIA Waiver for Xpert® Xpress MVP
-
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
-
Danaher CEO to Comment on Financial Performance
-
Danaher to Present at J.P. Morgan Healthcare Conference
-
Danaher Schedules Fourth Quarter 2023 Earnings Conference Call
-
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
-
Danaher Completes Acquisition of Abcam
-
Danaher Announces Quarterly Dividend
-
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
-
Danaher to Present at Evercore ISI HealthCONx Conference
-
Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023
-
Shareholders of Abcam Approve Proposed Acquisition by Danaher
-
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign
-
Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
-
Danaher Reports Third Quarter 2023 Results
-
Jonathan Milner Issues Statement Responding to the Glass Lewis Report
-
Integrated DNA Technologies Opens New Therapeutic Manufacturing Facility to Support Growing Demand in Genomic Medicine
-
Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company
-
Independent Directors of Abcam Highlight Compelling Reasons for Shareholders to Support Proposed Sale to Danaher
-
Jonathan Milner issues Open Letter to shareholders of Abcam plc
-
Abcam Files and Mails Scheme Circular Seeking Approval of Acquisition of Abcam by Danaher for $24.00 per Share
-
Danaher Corporation Completes Separation of Veralto Corporation
-
Veralto Set to Join S&P 500; Vestis to Join S&P MidCap 400; Others to Join S&P SmallCap 600
-
Battery Ventures Creates Latest Lab-Automation Technologies Platform with Investments in Skalar Analytical, PromoChrom and LCTech
-
Jonathan Milner issues Open Letter to shareholders of Abcam plc
-
Danaher Schedules Third Quarter 2023 Earnings Conference Call
-
Danaher to Provide Cepheid's Tuberculosis Test to the Global Fund at Cost
-
DHR FINAL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Danaher Corporation Investors to Secure Counsel Before Important September 15 Deadline in Securities Class Action – DHR
-
Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board
-
Danaher Announces Quarterly Dividend
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Danaher, Sea, and Syneos and Encourages Investors to Contact the Firm
-
DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $100,000 to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baxter, Rain, and Danaher, and Encourages Investors to Contact the Firm
-
DANAHER CORPORATION (NYSE: DHR) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Danaher Corporatio
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Danaher, Sea, and Syneos and Encourages Investors to Contact the Firm
-
Danaher and Veralto to Webcast Investor and Analyst Meeting
-
DANAHER CORPORATION DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Danaher Corporation (NYSE: DHR
-
Danaher to acquire Abcam for $24.00 per Share
-
Danaher to Acquire Abcam
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Rain, Proterra, and Danaher and Encourages Investors to Contact the Firm
Back to DHR Stock Lookup
